Completion of Facility Enables Initiation of Phase 3 Clinical Trial of Nepafenac in Patients Undergoing Cataract Surgery AUSTIN, Texas, Sept. 12, 2023 /PRNewswire/ -- Mati Therapeutics Inc. ("Mati") ...
Please provide your email address to receive an email when new articles are posted on . Among preoperative treatments to be considered are use of oral antivirals, continuation of topical steroids, ...
AUSTIN, Texas, Sept. 12, 2023 /PRNewswire/ -- Mati Therapeutics Inc. ("Mati") announced that it has completed and now occupies a facility dedicated to manufacturing all products formulated in Mati's ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results